Subtopic Deep Dive
EBV-Associated Lymphomas in HIV
Research Guide
What is EBV-Associated Lymphomas in HIV?
EBV-Associated Lymphomas in HIV refers to Epstein-Barr virus-driven lymphomas, such as Burkitt lymphoma and primary CNS lymphoma, occurring at elevated rates in HIV/AIDS patients due to immunosuppression.
These lymphomas arise from EBV infection in the context of HIV-induced immune deficiency, with incidence decreasing post-HAART introduction. Key studies quantify global infection-associated cancer burdens, including EBV-linked cases (Parkin, 2006; 2917 citations). Research tracks shifts in lymphoma subtypes since HAART era (Besson et al., 2001; 375 citations).
Why It Matters
EBV lymphomas in HIV patients highlight needs for optimized HAART to restore immunity and reduce malignancy risk, informing global oncology strategies in high-HIV-burden regions. Parkin (2006) estimates infection-associated cancers comprise significant fractions worldwide, guiding resource allocation. Besson et al. (2001) document HAART's impact on lymphoma incidence, supporting antiviral therapies. Thompson and Kurzrock (2004) link EBV to tumor development in immunocompromised hosts, influencing targeted interventions.
Key Research Challenges
Quantifying EBV-HIV Synergy
Distinguishing EBV-driven from HIV-only lymphomas requires precise attribution models amid confounding immunosuppression. Parkin (2006) uses population-based methods for global estimates, but HIV-specific data gaps persist. Plummer et al. (2016) apply synthetic analysis for 2012 burdens, highlighting methodological variances.
Post-HAART Lymphoma Shifts
Tracking evolving lymphoma subtypes post-HAART demands longitudinal cohorts tracking immune reconstitution effects. Besson et al. (2001) report incidence changes since HAART, noting persistent risks. Oksenhendler et al. (2002) identify high KSHV-related NHL in HIV-MCD overlap, complicating classification.
Therapeutic Response Variability
Immune recovery via ART alters lymphoma responses, but optimal regimens remain unclear. Thompson and Kurzrock (2004) detail EBV oncogenesis in immunocompromised states. Suárez (2006) models antigen-driven proliferation in marginal zone lymphomas, relevant to HIV contexts.
Essential Papers
The global health burden of infection‐associated cancers in the year 2002
Donald Maxwell Parkin · 2006 · International Journal of Cancer · 2.9K citations
Abstract Several infectious agents are considered to be causes of cancer in humans. The fraction of the different types of cancer, and of all cancers worldwide and in different regions, has been es...
Global burden of cancers attributable to infections in 2012: a synthetic analysis
Martyn Plummer, Catherine de Martel, Jérôme Vignat et al. · 2016 · The Lancet Global Health · 1.6K citations
Fondation de France.
Epstein-Barr Virus and Cancer
Matthew P. Thompson, Razelle Kurzrock · 2004 · Clinical Cancer Research · 789 citations
Abstract EBV was the first human virus to be directly implicated in carcinogenesis. It infects >90% of the world’s population. Although most humans coexist with the virus without serious seq...
Primary gastrointestinal lymphoma
Prasanna Ghimire · 2011 · World Journal of Gastroenterology · 457 citations
Gastrointestinal tract is the most common extranodal site involved by lymphoma with the majority being non-Hodgkin type. Although lymphoma can involve any part of the gastrointestinal tract, the mo...
Infection-associated lymphomas derived from marginal zone B cells: a model of antigen-driven lymphoproliferation
Felipe Suárez · 2006 · Blood · 440 citations
Non-Hodgkin lymphomas develop from nodal and extranodal lymphoid tissues. A distinct subset of extranodal lymphomas arising from B cells of the marginal zone (MZ) of mucosa-associated lymphoid tiss...
The Global Landscape of EBV-Associated Tumors
Claire Shannon‐Lowe, Alan B. Rickinson · 2019 · Frontiers in Oncology · 428 citations
Epstein-Barr virus (EBV), a gamma-1 herpesvirus, is carried as a life-long asymptomatic infection by the great majority of individuals in all human populations. Yet this seemingly innocent virus is...
High incidence of Kaposi sarcoma–associated herpesvirus–related non-Hodgkin lymphoma in patients with HIV infection and multicentric Castleman disease
Éric Oksenhendler, Emmanuelle Boulanger, Lionel Galicier et al. · 2002 · Blood · 408 citations
Multicentric Castleman disease (MCD) is a distinct type of lymphoproliferative disorder associated with inflammatory symptoms and interleukin 6 (IL-6) dysregulation. In the context of human immunod...
Reading Guide
Foundational Papers
Start with Parkin (2006) for global infection-cancer burdens (2917 citations), then Thompson and Kurzrock (2004) for EBV mechanisms (789 citations), followed by Besson et al. (2001) on HAART impacts (375 citations).
Recent Advances
Plummer et al. (2016) updates 2012 burdens (1584 citations); Shannon-Lowe and Rickinson (2019) maps EBV-tumor landscape (428 citations).
Core Methods
Epidemiological attribution fractions (Parkin, 2006); cohort incidence tracking post-HAART (Besson et al., 2001); antigen-driven models for marginal zone lymphomas (Suárez, 2006).
How PapersFlow Helps You Research EBV-Associated Lymphomas in HIV
Discover & Search
Research Agent uses searchPapers and citationGraph to map EBV-HIV lymphoma literature from Parkin (2006), revealing 2917 citations linking to Besson et al. (2001) on HAART impacts. exaSearch uncovers niche HIV-MCD overlaps from Oksenhendler et al. (2002); findSimilarPapers expands to Plummer et al. (2016) global analyses.
Analyze & Verify
Analysis Agent employs readPaperContent on Thompson and Kurzrock (2004) to extract EBV mechanisms in HIV, with verifyResponse (CoVe) checking claims against Parkin (2006). runPythonAnalysis performs GRADE grading on cohort data from Besson et al. (2001), enabling statistical verification of incidence reductions via pandas survival curves.
Synthesize & Write
Synthesis Agent detects gaps in post-HAART therapeutic data between Suárez (2006) and recent works, flagging contradictions in lymphoma attributions. Writing Agent uses latexEditText, latexSyncCitations for Besson et al. (2001), and latexCompile to generate review manuscripts; exportMermaid visualizes EBV-HIV pathway diagrams.
Use Cases
"Analyze survival trends in EBV lymphomas pre- and post-HAART from cohort studies."
Research Agent → searchPapers('HAART EBV lymphoma survival') → Analysis Agent → runPythonAnalysis (pandas on Besson 2001 data for Kaplan-Meier curves) → matplotlib plot of risk reductions.
"Draft LaTeX review on EBV-associated Burkitt lymphoma in HIV patients."
Synthesis Agent → gap detection (Parkin 2006 vs Plummer 2016) → Writing Agent → latexEditText (integrate Thompson 2004) → latexSyncCitations → latexCompile → PDF with EBV-oncology timeline.
"Find code for modeling EBV infection burdens in HIV populations."
Research Agent → paperExtractUrls (Parkin 2006 supplements) → paperFindGithubRepo → githubRepoInspect (epidemiology simulators) → runPythonAnalysis to adapt NumPy burden calculators.
Automated Workflows
Deep Research workflow conducts systematic review of 50+ papers from Parkin (2006) citationGraph, generating structured reports on EBV-HIV burdens with GRADE scores. DeepScan applies 7-step analysis with CoVe checkpoints to verify HAART effects in Besson et al. (2001). Theorizer builds hypotheses on EBV latency mechanisms from Thompson and Kurzrock (2004), chaining to exportMermaid diagrams.
Frequently Asked Questions
What defines EBV-associated lymphomas in HIV?
These are EBV-driven malignancies like Burkitt and CNS lymphomas in HIV patients, exacerbated by CD4 depletion (Thompson and Kurzrock, 2004).
What methods quantify their global burden?
Population-attributable fractions from epidemiological reviews, as in Parkin (2006) for 2002 and Plummer et al. (2016) synthetic analysis for 2012.
What are key papers?
Parkin (2006; 2917 citations) on infection cancers; Besson et al. (2001; 375 citations) on HAART changes; Thompson and Kurzrock (2004; 789 citations) on EBV-cancer links.
What open problems exist?
Predicting post-HAART persistent risks and distinguishing EBV from KSHV roles in HIV lymphomas, per Oksenhendler et al. (2002).
Research Viral-associated cancers and disorders with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching EBV-Associated Lymphomas in HIV with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers